Organ-on-Chip Market Research, 2030
The global organ-on-chip market was valued at $103.44 million in 2020, and is projected to reach $1.6 billion by 2030, growing at a CAGR of 31.1% from 2021 to 2030.Organ-on-chip is a type of artificial organ that simulates human organs. It is a multichannel 3D micro-fluidic cell culture device, which stimulates activities, mechanisms, and physiological responses of organs. The combination of labs-on-chips (LOCs) and cell biology has allowed researchers to examine human physiology in an organ-specific environment, resulting in the development of a new model of in vitro multicellular human organisms. This chip develops a narrow channel for the blood and air flow in organs including, lung, gut, brain, liver, and heart. These devices are developed on a microchip that contains continuously perfused chambers colonized by living cells arranged to stimulate tissues and organ level physiology. Organ-on-chip is a device that is used to nurture internal organs with the help of silicone.
Organ-on-chip is a potentially game changing technology that combines tissue engineering and microfluidics. These technologies are predicted to provide effective answers to long standing issues in medication discovery and individualized disease treatment. It plays a major role in drug development studies, thus boosting the organ-on-chip industry.
The global organ-on-chip market is driven by increase in its applications in the healthcare sector, rise in demand for drug screening, and surge in demand for lung-based organ culture & kidney applications. Surge in alternative of animal testing by research activities on organ-on-chip devices for new drug development is expected to majorly boost the organ-on-chip market in upcoming years.
In addition, surge in demand for organ-on-chip devices in the healthcare industry is expected to boost the global organ-on-chip market. Real-time imaging, in vitro analysis of biochemical, and genetic & metabolic activities of living cells in a functional tissue are some of the applications of organ-on-chip devices in the healthcare industry. Advancements in cell biology, microfabrication, and microfluidics have led to increase in adoption of organ-on-chips, thereby fueling the organ-on-chip market growth.
Increase in demand for organ-on-chips in drug screening, rise in demand for lung- & kidney-based organ culture devices is expected to boost the organ-on-chip market size. Moreover, the shortage of donor organs and availability of laboratory-engineered functional organs are expected to be a major advantage to cater to the growing demands of organs transplantation. However, high cost of the organ chip device and the development of organ-on-chip (OOC) technology is still in its nascent stage, and is expected to restrain growth of the market. Conversely, considerable rise in healthcare expenditure across the globe has led to the increase of organ-on-chip market size. Emerging economies possess high potential for organ-on-chip market. Increase in number of chronic diseases, high requirement for organ transplantation, and surge in animal testing for drug discovery are expected to drive demand for these products over the next few years
Organ-on-chip Market segmentation
The organ-on-chip market analysis is segmented on the basis of type and region. Depending on type, it is classified into heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip, and lung-on-chip.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).
Segment Review
Depending on product, the lung-on-chip segment of the organ-on-chip industry dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to lower lung transplantations, which has led to development of laboratory engineered chips to mimic their functions and for drug screening for respiratory disorders.
North America exhibited the global organ-on-chip market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of technologically advanced models, presence of key players, and rise in R & D activities for drug discovery and development. However, Asia-Pacific is anticipated to witness notable organ-on-chip market opportunity, owing to increase in R&D activities, increase in healthcare investment, and various strategies among key players. Moreover, India and China are expected to grow at high CAGR in the Asia-Pacific organ-on-chip market forecast.
The key players operating in the global organ-on-chip market are AxoSim Technologies LLC., BICO Group AB(Visikol), CN Bio Innovations Limited, Elveflow, Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc., and Tara Biosystems.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the organ-on-chip market analysis from 2020 to 2030 to identify the prevailing organ-on-chip market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the organ-on-chip market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global organ-on-chip market trends, key players, market segments, application areas, and market growth strategies.
Organ-on-Chip Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Region |
|
 Key Market Players | BICO Group AB(Visikol), Elveflow, Organovo Holdings, Inc., Emulate, Inc., Insphero AG, CN Bio Innovations Limited, AxoSim Technologies LLC, Mimetas B.V., Tara Biosystems, Nortis Inc. |
Analyst Review
This section provides opinions of top-level CXOs in the organ-on-chip industry. According to CXOs, organ-on-chip is expected to witness a high adoption rate with an increase in distinct indications and interventions, due to surge in disease load, rise in drug discovery& development, drug screening, and clinical trials.
CXOs further state that, organ-on-chip are potential tools for realistic modeling of human physiology and pathology due to the synergistic confluence of microfabrication technologies and tissue engineering. These technologies are expected to provide effective solutions to long-standing issues in medication discovery and individualized disease treatment. The global organ-on-chip market witnessed significant momentum in the healthcare industry and pharmaceutical sector, owing to favorable government policies, conducive regulations abiding organ-on-chip, and growth in the alternative solutions required for animal testing. However, the high development & manufacturing cost of organ-chip-devices is expected to restrict the market growth.
North America is expected to witness the highest growth, in terms of revenue during the forecast period, owing to rise in the adoption of technologically advanced research infrastructure, the presence of key players, and advancements in healthcare investments. However, Asia-Pacific is expected to grow significantly, owing to its high R&D activities, increase in investment for technological advancement from key players, and the government.
The total market value of organ-on-chip market is $103.44 million in 2020.
Lung-on-chip segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to lower lung transplantations, which has led to development of laboratory engineered chips to mimic their functions and for drug screening for respiratory disorders and is expected to drive the segment.
Increase in prevalence of chronic diseases, rising patient pool and various technological advancements in organ-on-chip is anticipated to drive the market in the forecast period.
Top companies such as AxoSim Technologies LLC., BICO Group AB(Visikol), CN Bio Innovations Limited, Elveflow, Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc., and Tara Biosystems held a high market position in 2020.
North America is projected to account for a major share of the global organ-on-chip market during the forecast period. U.S. dominated the North America organ-on-chip market owing to increased chronic diseases, adoption of technologically advanced therapies and surge in R & D across the country.
Loading Table Of Content...
